RAS and ROS in rhabdomyosarcoma

Cancer Cell
Minsi ZhangDavid G Kirsch

Abstract

The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.

References

Dec 18, 2013·Cancer Cell·Xiang ChenUNKNOWN St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project

❮ Previous
Next ❯

Citations

Jul 26, 2015·Cell Cycle·Eugenio Monti, Alessandro Fanzani
Oct 1, 2015·Sarcoma·Xin SunZhenfeng Duan
Aug 8, 2017·International Journal of Molecular Sciences·Alessandro Fanzani, Maura Poli
Jul 24, 2021·Journal of Hematology & Oncology·Richard MiallotPhilippe Naquet

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.